ReviewInternational journal of molecular sciences2021
Understanding the Future Prospects of Synergizing Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgery with Ceramics and Regenerative Cellular Therapies.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Integrating Structures and Biology: Cellular and Molecular Interactions with Functionally Graded Spinal Cage Designs.International journal of molecular sciences · 2026Review
- Three-Dimensional Printing of a Spinal Interbody: Design Principles, Biomaterials, and Translational Considerations.Journal of functional biomaterials · 2026Review
- Osteointegration and Fusion After TLIF: Trabecular Titanium Cage with SVF-Hydrogel Compared with PEEK Cage.Orthopedic reviews · 2026Article
- Application of Biocomposite Hydrogel With Developed Trabecular Cage in Lumbar Interbody Fusion: A Clinical Case Report.Clinical medicine insights. Case reports · 2025Article
- Article
- Osteobiologies for Spinal Fusion from Biological Mechanisms to Clinical Applications: A Narrative Review.International journal of molecular sciences · 2023Review
- Concepts of Regeneration for Spinal Diseases in 2023.International journal of molecular sciences · 2023Article
- History and Evolution of the Minimally Invasive Transforaminal Lumbar Interbody Fusion.Neurospine · 2022Article
- Pretreatment of nucleus pulposus mesenchymal stem cells with appropriate concentration of HStem cell research & therapy · 2022Article
- Application and thinking of minimally invasive transforaminal lumbar interbody fusion in degenerative lumbar diseases.Annals of translational medicine · 2022Article
- Concepts of Regeneration for Spinal Diseases in 2021.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforaminal lumber interbody fusion (TLIF) is the last resort to address the lumber degenerative disorders such as spondylolisthesis, causing lower back pain. The current surgical intervention for these abnormalities includes open TLIF. However, in recent years, minimally invasive TLIF (MIS-TLIF) has gained a high momentum, as it could minimize the risk of infection, blood loss, and post-operative complications pertaining to fusion surgery. Further advancement in visualizing and guiding techniques along with grafting cage and materials are continuously improving the safety and efficacy of MIS-TLIF. These assistive techniques are also playing a crucial role to increase and improve the learning curve of surgeons. However, achieving an appropriate output through TLIF still remains a challenge, which might be synergized through 3D-printing and tissue engineering-based regenerative therapy. Owing to their differentiation potential, biomaterials such as stem/progenitor cells may contribute to restructuring lost or damaged tissues during MIS-TLIF, and this therapeutic efficacy could be further supplemented by platelet-derived biomaterials, leading to improved clinical outcomes. Thus, based on the above-mentioned strategies, we have comprehensively summarized recent developments in MIS-TLIF and its possible combinatorial regenerative therapies for rapid and long-term relief.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.